Biomedicines (Sep 2022)

Antispike Immunoglobulin-G (IgG) Titer Response of SARS-CoV-2 mRNA-Vaccine (BNT162b2): A Monitoring Study on Healthcare Workers

  • Alessio Danilo Inchingolo,
  • Giuseppina Malcangi,
  • Sabino Ceci,
  • Assunta Patano,
  • Alberto Corriero,
  • Daniela Azzollini,
  • Grazia Marinelli,
  • Giovanni Coloccia,
  • Fabio Piras,
  • Giuseppe Barile,
  • Vito Settanni,
  • Antonio Mancini,
  • Nicole De Leonardis,
  • Grazia Garofoli,
  • Giulia Palmieri,
  • Ciro Gargiulo Isacco,
  • Biagio Rapone,
  • Megan Jones,
  • Ioana Roxana Bordea,
  • Gianluca Martino Tartaglia,
  • Antonio Scarano,
  • Felice Lorusso,
  • Luigi Macchia,
  • Angela Maria Vittoria Larocca,
  • Silvio Tafuri,
  • Giovanni Migliore,
  • Nicola Brienza,
  • Gianna Dipalma,
  • Francesco Inchingolo

DOI
https://doi.org/10.3390/biomedicines10102402
Journal volume & issue
Vol. 10, no. 10
p. 2402

Abstract

Read online

The secretion of IgG SARS-CoV-2 antispike antibodies after vaccination with BNT162b2 and the protection represent the response of the human organism to the viral vector symptomatic infections. The aim of the present investigation was to evaluate the immune reaction in health workers of the Polyclinic of Bari to identify the relationship of antispike titers with blood type, sex, age, and comorbidities. This prospective observational study (RENAISSANCE) had as its primary endpoint the assessment of serologic response to BNT162b2 at three blood titers: the first at 60 days after the second dose (3 February 2021); the second titer at 75 days after the first titer; and the third titer at 130 days after the second titer. Out of 230 enrolled staff members, all responded excellently to the mRna Pfizer (BNT162b) vaccine. Only one patient, 40 days after the second dose (3 February 2021), was positive on the swab control performed on 15 March 2021, although completely asymptomatic, and was negative on the subsequent molecular swab performed on 30 March 2021. All the patients responded to the mRNA Pfizer (BNT162b) vaccine with an antispike IgG level above 500 BAU/mL at the first antispike protein essay (60 days after the second dose on 3 April 2021); at the second titer (75 days after the first titer on 20 June 2021), 4 (1.7% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL; at the third titer (130 days after the second titer on 30 June 2021, which means 9 months after the second dose), 37 (16.1% of 230 enrolled) patients showed an antispike IgG level under 500 BAU/mL. The data analysis demonstrated that patients belonging to blood group 0, regardless of their rhesus factor, showed the strongest level of antibodies compared to the other groups. No dependency was found between low antibodies level and sex or age. Molecular swab controls were performed every 15th of the month continuously. However, the enrolled patients’ activity was at high risk because they carried out medical activities such as dental and surgical as well with droplets of water vaporized by the effect of turbines, piezosurgery. The vaccination campaign among health workers of the Policlinico of the University of Bari “Aldo Moro” led to an excellent serological response and the complete absence of COVID-19 incident cases, so the antibody response was excellent. The COVID-19 vaccine booster shot should be administered after 9 months and not without prompt antispike titer detection to assess if any sign of waning immunity is present in that specific patient.

Keywords